Dr. Feldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3440 N Broad St
Philadelphia, PA 19140Phone+1 215-707-1673Fax+1 215-707-3946
Summary
- Dr. Arthur Feldman is a cardiologist in Philadelphia, PA who is affiliated with Temple Universities School of Medicine where he was the Executive Dean and Chief Academic Officer of the Health System. Prior to that he was the McGee Professor and Chair of the Department of Medicine at Thomas Jefferson University Hospital and Jefferson Medical College. He began his administrative career at the University of Pittsburgh where he was the Harry S. Tack Professor of Medicine and Chief of the Division of Cardiology and the Director of the Cardiovascular Institute of UPMC. He received his medical degree from Louisiana State University School of Medicine in Shreveport and his PhD from the University of Maryland. His academic career began at the Johns Hopkins School of Medicine where he served as the Director of Heart Failure Research and Co-Director of the Belfer Laboratories. An internationally recognized expert in heart failure he served as President of the HFSA, President of the Association of Professors of Cardiology and was recently elected as a Counselor of the ACCA. He is also an elected member of the Johns Hopkins University Society of Scholars, the ASCI and the AAP. A Lifetime Achievement Awardee of the HFSA, He received the Barry Coller Award from the Association for Clinical and Translational and the Distinguished Scientist Award from the American College of Cardiology in 2019. The founding editor of two journals of Translational science, Feldman’s own work has been cited over 60,000 times according to Google Scholar. has been in practice 36 years during which time he has frequently been recognized by “Best Doctors in America.” Most recently his clinical practice and research have focused on gene therapy for patients with hereditary cardiomyopathy due to a mutation in BAG3 - work that led him to found Renovacor, Inc., a venture-funded biotechnology company.
Education & Training
- Johns Hopkins UniversityFellowship, Cardiovascular Disease, 1984 - 1985
- Johns Hopkins UniversityResidency, Internal Medicine, 1981 - 1984
- LSU School of Medicine in ShreveportClass of 1981
- Johns Hopkins University School of MedicinePost-Doctoral Fellowship, 1974 - 1977
- University of MarylandMS, PhD, Physiology, 1970 - 1974
Certifications & Licensure
- PA State Medical License 1994 - 2024
- MD State Medical License 1986 - 2000
- LA State Medical License 1981 - 1987
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Elected senior member National Academy of Inventors, Washington DC, 2023
- Elected member Association of American Physicians
- Distinguished Scientist Award American College of Cardiology, 2019
- Join now to see all
Publications & Presentations
PubMed
- Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co-Occurrence of P63A and P380SVariants.Thomas G Martin, Hana Pak, Glenn S Gerhard, Salim Merali, Carmen Merali
Journal of the American Heart Association. 2023-12-19 - 7 citationsBag3 Regulates Mitochondrial Function and the Inflammasome Through Canonical and Noncanonical Pathways in the Heart.JuFang Wang, Dhadendra Tomar, Thomas G Martin, Shubham Dubey, Praveen K Dubey
JACC. Basic to Translational Science. 2023-07-01 - Precision Medicine: Solving the Mystery of Myocarditis in the Aftermath of SARS-CoV-2.Arthur M Feldman, Edward K Kasper, Hui-Qi Qu
JACC. Heart Failure. 2023-04-01
Press Mentions
- Heart Failure Strategically Focused Research Network: Summary of Results and Future DirectionsSeptember 8th, 2022
- Physics to Genetics: New Treatments for Hereditary Heart DiseaseJuly 28th, 2021
- Philadelphia Gene Therapy Developer Spun Out of Temple to Raise over $100M via SPACMarch 23rd, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: